GK,一个被低估了的创新药宝藏靶点。在此前CDS(中华医学会糖尿病学分会)年度学术会议上(11月19-22日,西安),葡萄糖激酶激活剂(GKA)类口服糖尿病治疗药物多格列艾汀(dorzagliatin)再次成为焦点方案。常年躬耕于中国糖尿病的科研与基层防治领域,南京大学医学院附属鼓楼医院朱大龙教授感慨于糖尿病创新药物的“中国方案”正在成为本土糖尿病临床防治的主流力量。曾几何时,占全球糖尿病人口数...
Source LinkGK,一个被低估了的创新药宝藏靶点。在此前CDS(中华医学会糖尿病学分会)年度学术会议上(11月19-22日,西安),葡萄糖激酶激活剂(GKA)类口服糖尿病治疗药物多格列艾汀(dorzagliatin)再次成为焦点方案。常年躬耕于中国糖尿病的科研与基层防治领域,南京大学医学院附属鼓楼医院朱大龙教授感慨于糖尿病创新药物的“中国方案”正在成为本土糖尿病临床防治的主流力量。曾几何时,占全球糖尿病人口数...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.